Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Authors' conclusion
These results from diverse patient populations in routine care settings across Europe and Asia demonstrate that initiation of empagliflozin compared to DPP-4i results in favourable cardioprotective effects regardless of pre-existing CVD or HF status.
Study context
- Population
- Adults with T2D initiating empagliflozin or DPP-4i in 2014–2018/19, routine care in 11 countries in Europe and Asia
- Participants
- 85,244 PS-matched patient pairs
- Exposure
- Empagliflozin vs DPP-4i initiation
- Outcome
- Hospitalisation for HF (hospitalisation for heart failure (HHF)), myocardial infarction (MI), stroke
- Follow-up
- Mean 0.7 years
Methodological detailspropensity-score matched, multinational (11 countries, Europe and Asia), routine care, stratified by pre-existing cardiovascular disease (CVD) and HF, random-effects meta-analysis of country-specific results
- Propensity-score matched
- Multinational (11 countries, Europe and Asia)
- Routine care
- Stratified by pre-existing CVD and HF
- Random-effects meta-analysis of country-specific results
Main finding
As reported in the abstract
Primary outcomes in patients with pre-existing CVD
Empagliflozin vs DPP-4iHazard ratio (95% CI)
HHF
0.74(0.64–0.86)
Stroke
0.79(0.67–0.94)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| Secondary outcomes in patients with pre-existing CVDEmpagliflozinvs DPP-4iCV mortality | 0.55 (0.38–0.80) | |
| Secondary outcomes in patients with pre-existing CVDEmpagliflozinvs DPP-4iHHF or CV mortality | 0.57 (0.48–0.67) | |
| 0.20.5125Hazard ratio (log scale) |
Subgroups without pre-existing CVD, and with and without pre-existing HF
- Similar patterns observed
Original publication
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia. Cardiovasc Diabetol. Published 31 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →